Biochemical recurrence after localized treatment

被引:19
作者
Amling, Christopher L. [1 ]
机构
[1] Univ Alabama Birmingham, Div Urol, Birmingham, AL 35294 USA
关键词
D O I
10.1016/j.ucl.2005.12.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The quoted incidence of biochemical recurrence (BCR) after localized treatment varies significantly and depends on numerous well-known prognostic factors; however, it likely occurs in at least 30%-40% of patients who receive localized treatment. Because the clinical significance of BCR is often unclear, and depends in many cases on unknown factors, it is difficult to select the best treatment and determine when best to institute that therapy. This review examines some of the issues associated with BCR and attempts to shed some light on this common but controversial clinical scenario. Some treatment strategies discussed in this article include salvage radiotherapy after radical prostatectomy, salvage therapy after radiotherapy, and hormonal therapy.
引用
收藏
页码:147 / +
页数:14
相关论文
共 79 条
[51]   Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen [J].
Patel, A ;
Dorey, F ;
Franklin, J ;
deKernion, JB .
JOURNAL OF UROLOGY, 1997, 158 (04) :1441-1445
[52]   Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy [J].
Pinover, WH ;
Horwitz, EM ;
Hanlon, AL ;
Uzzo, RG ;
Hanks, GE .
CANCER, 2003, 97 (04) :1127-1133
[53]   Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer [J].
Pisansky, TM ;
Kozelsky, TF ;
Myers, RP ;
Hillman, DW ;
Blute, ML ;
Buskirk, SJ ;
Cheville, JC ;
Ferrigni, RG ;
Schild, SE .
JOURNAL OF UROLOGY, 2000, 163 (03) :845-850
[54]  
POLLACK A, 1994, CANCER, V74, P670, DOI 10.1002/1097-0142(19940715)74:2<670::AID-CNCR2820740220>3.0.CO
[55]  
2-8
[56]   Natural history of progression after PSA elevation following radical prostatectomy [J].
Pound, CR ;
Partin, AW ;
Eisenberger, MA ;
Chan, DW ;
Pearson, JD ;
Walsh, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1591-1597
[57]   Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: Correlation with histologic characteristics of the primary cancer [J].
Pruthi, RS ;
Johnstone, I ;
Tu, IP ;
Stamey, TA .
UROLOGY, 1997, 49 (05) :737-742
[58]   Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy [J].
Raj, GV ;
Partin, AW ;
Polascik, TJ .
CANCER, 2002, 94 (04) :987-996
[59]  
Ravery V, 1999, Semin Urol Oncol, V17, P127
[60]  
Roberts SG, 2001, MAYO CLIN PROC, V76, P576